Recent events
Recent events tied to this brand in public sources.
Back to profile9 entries
2021
Allergan agrees to pay up to $200 million in New York opioid settlement
Allergan agreed to pay New York state and Nassau and Suffolk counties up to $200 million in a settlement related to its role in the opioid epidemic. The lawsuit claims manufacturers and distributors downplayed addiction risks; the source does not report a court determination of those claims.
2021
FDA approves VUITY for presbyopia
The FDA approved Allergan's VUITY eye drops for the treatment of presbyopia in adults.
2020
AbbVie completes acquisition of Allergan
AbbVie announced that it had completed its acquisition of Allergan; the transaction had received the required government regulatory approvals and approval from the High Court of Ireland.
2020
Allergan receives 2020 ENERGY STAR Partner of the Year Sustained Excellence Award
Allergan announced that it received the 2020 ENERGY STAR Partner of the Year Sustained Excellence Award from the US Environmental Protection Agency, recognizing its energy management and efficiency.
2020
Allergan opens biologics facility in Westport
Allergan opened a €160 million biologics facility at its Westport campus in County Mayo. The company said the expansion would allow it to increase manufacturing of its flagship products and create 63 new jobs.
2019
FDA approves Ubrelvy for acute migraine treatment
The FDA approved Ubrelvy (ubrogepant), marketed by Allergan, for the acute treatment of migraine in adults.
2019
Allergan reports third-quarter 2019 results
Allergan reported third-quarter 2019 financial results, including GAAP net revenues of $4.05 billion, up 3.6 percent from the prior-year quarter.
2019
Allergan raises 2019 revenue guidance
In its third-quarter results announcement, Allergan raised its full-year 2019 net revenue guidance and reaffirmed its guidance for non-GAAP performance net income per share.
2019
FDA approves BOTOX for pediatric lower limb spasticity
The FDA approved Allergan’s supplemental application to expand BOTOX (onabotulinumtoxinA) treatment to pediatric patients aged 2 to 17 with lower limb spasticity, excluding spasticity caused by cerebral palsy.